Foram encontradas 160 questões.
4257822
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
Read the sentences and evaluate the meanings and
grammatical uses of the highlighted phrasal verbs.
( ) In "The research team carried out several interviews," carried out means conducted.
( ) In "The school turned down the proposal," the object pronoun may be correctly placed as in "The school turned it down."
( ) In "The volunteer looked after the children," the phrasal verb is separable and may be rewritten as "The volunteer looked the children after."
( ) In "She eventually got over the disappointment," got over means examined the disappointment carefully.
Mark T for true statements and F for false statements. Then select the alternative that presents the CORRECT sequence
( ) In "The research team carried out several interviews," carried out means conducted.
( ) In "The school turned down the proposal," the object pronoun may be correctly placed as in "The school turned it down."
( ) In "The volunteer looked after the children," the phrasal verb is separable and may be rewritten as "The volunteer looked the children after."
( ) In "She eventually got over the disappointment," got over means examined the disappointment carefully.
Mark T for true statements and F for false statements. Then select the alternative that presents the CORRECT sequence
Provas
Questão presente nas seguintes provas
A public school organizes an English-language
information project about access to municipal services.
Students analyse forms and websites, identify barriers to
comprehension and produce plain-language guides for
different audiences. Which assessment design most
coherently reflects the formative and civic dimensions of
the project?
Provas
Questão presente nas seguintes provas
During a lesson on requesting information, students first
listen to a short exchange at a train station. They identify expressions used to ask about departure times, adapt the
dialogue to new destinations, and perform similar
interactions with different classmates. The teacher
provides brief feedback on clarity and appropriateness.
The lesson is most consistent with:
Provas
Questão presente nas seguintes provas
4257819
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
Four students must produce a podcast in English. One
member misses deadlines, another begins making
decisions without consultation, and the remaining
students avoid discussing the conflict. The teacher
decides to structure a group review meeting. Which
sequence best promotes assertive communication and
shared responsibility?
Provas
Questão presente nas seguintes provas
An English teacher organizes a unit in which students
compare posts, news reports and public-service
messages about the same environmental issue. They
examine audience, purpose, vocabulary and source
credibility before creating a bilingual awareness
campaign for the school community. The activity most
appropriately treats English as:
Provas
Questão presente nas seguintes provas
4257817
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Provas
Questão presente nas seguintes provas
4257816
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
( ) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
( ) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
( ) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
( ) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
Provas
Questão presente nas seguintes provas
4257815
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
- Interpretação de texto | Reading comprehension
- Gramática - Língua InglesaOrações condicionais | Conditional Clauses
- Gramática - Língua InglesaVerbos | VerbsPresente simples | Simple present
- Gramática - Língua InglesaVerbos | VerbsVerbos modais | Modal verbs
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
Provas
Questão presente nas seguintes provas
4257814
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Provas
Questão presente nas seguintes provas
4257813
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
Provas
Questão presente nas seguintes provas
Cadernos
Caderno Container